Marc Bourlière

26.2k total citations · 2 hit papers
305 papers, 8.8k citations indexed

About

Marc Bourlière is a scholar working on Hepatology, Epidemiology and Infectious Diseases. According to data from OpenAlex, Marc Bourlière has authored 305 papers receiving a total of 8.8k indexed citations (citations by other indexed papers that have themselves been cited), including 255 papers in Hepatology, 218 papers in Epidemiology and 41 papers in Infectious Diseases. Recurrent topics in Marc Bourlière's work include Hepatitis C virus research (221 papers), Liver Disease Diagnosis and Treatment (170 papers) and Hepatitis B Virus Studies (130 papers). Marc Bourlière is often cited by papers focused on Hepatitis C virus research (221 papers), Liver Disease Diagnosis and Treatment (170 papers) and Hepatitis B Virus Studies (130 papers). Marc Bourlière collaborates with scholars based in France, United States and Germany. Marc Bourlière's co-authors include Philippe Halfon, Stanislas Pol, Guillaume Pénaranda, Denis Ouzan, Christophe Hézode, Laurent Castéra, Victor de Lédinghen, Christophe Renou, Geoffrey Dusheiko and Jean–Pierre Bronowicki and has published in prestigious journals such as New England Journal of Medicine, Annals of Internal Medicine and Gastroenterology.

In The Last Decade

Marc Bourlière

290 papers receiving 8.5k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Telaprevir and Peginterferon with or without Ribavirin for Chronic HCV Infection

2009 771 citations Stanislas Pol, Jean–Pierre Bronowicki et al. profile →
Retreatment of HCV with ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin

2014 395 citations Marc Bourlière, Heiner Wedemeyer et al. profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author						Papers	Cites
Marc Bourlière	7.6k	7.0k	1.3k	499	462	305	8.8k
Christophe Hézode	8.0k 1.1×	7.3k 1.0×	1.6k 1.2×	718 1.4×	336 0.7×	175	8.9k
Douglas T. Dieterich	6.9k 0.9×	7.0k 1.0×	2.3k 1.7×	255 0.5×	359 0.8×	258	9.3k
Kenneth E. Sherman	6.7k 0.9×	5.8k 0.8×	2.2k 1.6×	433 0.9×	375 0.8×	250	8.7k
Paul J. Pockros	6.5k 0.9×	6.2k 0.9×	1.1k 0.8×	650 1.3×	580 1.3×	190	8.5k
Robert P. Perrillo	8.4k 1.1×	8.9k 1.3×	1.0k 0.8×	621 1.2×	469 1.0×	119	10.1k
George Marinos	7.0k 0.9×	6.2k 0.9×	924 0.7×	753 1.5×	344 0.7×	63	8.0k
Alessandra Mangia	6.4k 0.8×	6.1k 0.9×	759 0.6×	618 1.2×	500 1.1×	202	7.7k
Stephanos J. Hadziyannis	13.7k 1.8×	13.7k 2.0×	1.5k 1.2×	448 0.9×	326 0.7×	172	14.9k
Lennox J. Jeffers	6.4k 0.9×	6.4k 0.9×	738 0.6×	294 0.6×	1.1k 2.3×	136	8.3k
Massimo Puoti	7.0k 0.9×	6.6k 1.0×	2.5k 1.9×	384 0.8×	255 0.6×	263	9.1k

Countries citing papers authored by Marc Bourlière

Since Specialization

Citations

This map shows the geographic impact of Marc Bourlière's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Marc Bourlière with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Marc Bourlière more than expected).

Fields of papers citing papers by Marc Bourlière

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Marc Bourlière. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Marc Bourlière. The network helps show where Marc Bourlière may publish in the future.

Co-authorship network of co-authors of Marc Bourlière

This figure shows the co-authorship network connecting the top 25 collaborators of Marc Bourlière. A scholar is included among the top collaborators of Marc Bourlière based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Marc Bourlière. Marc Bourlière is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Lim, Seng Gee, Marc Bourlière, Nathalie Ganne‐Carrié, et al.. (2025). HBsAg decline and clearance with peg-IFN therapy added to nucleos(t)ide analogues: an individual participant data meta-analysis of prospective trials (PROSPER). Gut. gutjnl–2025. 1 indexed citations

Agarwal, Kosh, Marı́a Buti, Florian van Bömmel, et al.. (2024). JNJ-73763989 and bersacapavir treatment in nucleos(t)ide analogue-suppressed patients with chronic hepatitis B: REEF-2. Journal of Hepatology. 81(3). 404–414. 22 indexed citations

Asselah, Tarik, Pietro Lampertico, Soo Aleman, et al.. (2024). Bulevirtide Monotherapy Is Safe and Well Tolerated in Chronic Hepatitis Delta: An Integrated Safety Analysis of Bulevirtide Clinical Trials at Week 48. Liver International. 45(4). e16174–e16174. 5 indexed citations

Barré, Tangui, Marc Bourlière, Lucia Parlati, et al.. (2023). Hepatitis C virus cure from direct‐acting antivirals and mortality: Are people with and without a history of injection drug use in the same boat? (ANRS CO22 Hepather cohort). Drug and Alcohol Review. 43(3). 718–731.

Adhoute, Xavier, Guillaume Pénaranda, Thomas Wolf, et al.. (2023). Intrahepatic Cholangiocarcinoma and Hepatocellular Carcinoma: Real-life Data on Liver Disease, Treatment and Prognosis. Journal of Clinical and Translational Hepatology. 0(0). 0–0. 4 indexed citations

Riveiro‐Barciela, Mar, et al.. (2023). Management of chronic HBV‐HDV patients chronic HBV‐HDV infection: A review on new management options. United European Gastroenterology Journal. 12(2). 210–218. 4 indexed citations

Younossi, Zobair M., Andrei Racila, Andrew J. Muir, et al.. (2021). Long-term Patient-Centered Outcomes in Cirrhotic Patients With Chronic Hepatitis C After Achieving Sustained Virologic Response. Clinical Gastroenterology and Hepatology. 20(2). 438–446. 10 indexed citations

Pol, Stanislas, Philippe Sogni, Hélène Fontaine, et al.. (2021). Direct, indirect and total effect of HIV coinfection on the risk of non‐liver‐related cancer in hepatitis C virus‐infected patients treated by direct‐acting antivirals: a mediation analysis. HIV Medicine. 22(10). 924–935. 1 indexed citations

Younossi, Zobair M., Maria Stepanova, K. Rajender Reddy, et al.. (2018). Viral eradication is required for sustained improvement of patient‐reported outcomes in patients with hepatitis C. Liver International. 39(1). 54–59. 24 indexed citations

10.

Younossi, Zobair M., Maria Stepanova, Tarik Asselah, et al.. (2017). Hepatitis C in Patients With Minimal or No Hepatic Fibrosis: The Impact of Treatment and Sustained Virologic Response on Patient-Reported Outcomes. Clinical Infectious Diseases. 66(11). 1742–1750. 18 indexed citations

11.

Younossi, Zobair M., Maria Stepanova, Stanislas Pol, et al.. (2015). The impact of ledipasvir/sofosbuvir on patient‐reported outcomes in cirrhotic patients with chronic hepatitis C: the SIRIUS study. Liver International. 36(1). 42–48. 45 indexed citations

12.

Zeuzem, Stefan, Vincent Soriano, Tarik Asselah, et al.. (2014). Efficacy and Safety of Faldaprevir, Deleobuvir, and Ribavirin in Treatment-Naive Patients with Chronic Hepatitis C Virus Infection and Advanced Liver Fibrosis or Cirrhosis. Antimicrobial Agents and Chemotherapy. 59(2). 1282–1291. 8 indexed citations

13.

Halfon, Philippe, Marc Bourlière, Denis Ouzan, et al.. (2010). 1167 IL-28 GENE VARIATION PREDICTS WHO WILL RESPOND TO INTERFERON-BASED TREATMENT OF CHRONIC HEPATITIS C IN A FRENCH COHORT. Journal of Hepatology. 52. S451–S451. 2 indexed citations

14.

Mallet, Vincent, Valérie Dhalluin-Venier, Marc Bourlière, et al.. (2008). The accuracy of the FIB‐4 index for the diagnosis of mild fibrosis in chronic hepatitis B. Alimentary Pharmacology & Therapeutics. 29(4). 409–415. 91 indexed citations

15.

Poynard, Thierry, Philippe Halfon, Laurent Castéra, et al.. (2007). Variability of the area under the receiver operating characteristic curves in the diagnostic evaluation of liver fibrosis markers: impact of biopsy length and fragmentation. Alimentary Pharmacology & Therapeutics. 25(6). 733–739. 81 indexed citations

16.

Bourlière, Marc. (2003). [Transmission of hepatitis B and C viruses from caregiver to patients: myths and reality].. PubMed. 27(3 Pt 1). 291–3. 1 indexed citations

17.

Peters, Marion G., Hie‐Won Hann, Paul Martin, et al.. (2003). Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B 1 1The Adefovir Dipivoxil International 461 Study Group includes the following: N. Afdhal (Beth Israel Deaconess Medical Center, Boston, MA); P. Angus (Austin and Repatriation Medical Centre, Melbourne, Australia); Y. Benhamou (Hopital La Pitie Salpetriere, Paris, France); M. Bourliere (Hopital Saint Joseph, Marseille, France); P. Buggisch (Universitaetsklinikum Eppendorf, Department of Medicine, Hamburg, Germany); P. Couzigou (Hopital Haut Leveque, Pessac, France); P. Ducrotte and G. Riachi (Hopital Charles Nicolle, Rouen, France); E. Jenny Heathcote (Toronto Western Hospital, Toronto, Ontario, Canada); H. W. Hann (Jefferson Medical College, Philadelphia, PA); I. Jacobson (New York Presbyterian Hospital, New York, NY); K. Kowdley (University of Washington Hepatology Center, Seattle, WA); P. Marcellin (Hopital Beaujon, Clichy, France); P. Martin (Cedars-Sinai Medical Center, Los Angeles, CA); J. M. Metreau (Centre Hospitalier Universitaire Henri Mondor, Creteil, France); M. G. Peters (University of California, San Francisco, San Francisco, CA); R. Rubin (Piedmont Hospital, Atlanta, GA); S. Sacks (Viridae Clinical Sciences, Inc., Vancouver, Canada); H. Thomas (St. Mary’s Hospital, London, England); C. Trepo (Hopital Hôtel Dieu, Lyon, France); D. Vetter (Hopital Civil, Strasbourg, France); C. L. Brosgart, R. Ebrahimi, J. Fry, C. Gibbs, K. Kleber, J. Rooney, M. Sullivan, P. Vig, C. Westland, M. Wulfsohn, and S. Xiong (Gilead Sciences, Inc., Foster City, CA); D. F. Gray (GlaxoSmithKline, Greenford, Middlesex, England); R. Schilling and V. Ferry (Parexel International, Waltham, MA); and D. Hunt (Covance Laboratories, Princeton, NJ).. Gastroenterology. 126(1). 91–101. 440 indexed citations

18.

Bourlière, Marc, Philippe Halfon, & Isabelle Portal. (2002). Hépatite chronique C traitement des groupes particuliers.. Gastroentérologie Clinique et Biologique. 26. 238–247. 1 indexed citations

19.

Rotily, Michel, Sandrine Loubière, Judith M. Nixon, et al.. (1997). Faut-il dépister l'hépatite C? Analyse socio(-)économique de différentes stratégies de dépistage de l'hépatite chronique C dans la population française.. Gastroentérologie Clinique et Biologique. 21. 2 indexed citations

20.

Bourlière, Marc, Yves Patrice Le Treut, D Arnoux, et al.. (1990). Acute Budd-Chiari syndrome with hepatic failure and obstruction of the inferior vena cava as presenting manifestations of hereditary protein C deficiency.. Gut. 31(8). 949–952. 29 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact